These diabetes devices are set to launch in 2024

The Stelo glucose monitor. [Image courtesy of Dexcom]The diabetes space continues to innovate and it doesn’t look like that’s stopping any time soon, with 2024 set to be another banner year.

At the end of 2023, we compiled a list of the 10 biggest diabetes technology stories of the year. Some of those stories didn’t end in 2023, though, as a few major product launches loom on the horizon.

New CGMs, insulin pumps and combinations of the two will all be coming to the market over the next several months. Here are some of the most highly-anticipated product launches set to take place in the diabetes space in 2024 — plus some of the tech that’s already launched:

Diabetes launches on the horizon Medtronic’s new pump-sensor combo

In January, Medtronic won CE mark for its MiniMed 780G automated insulin delivery system with the Simplera Sync sensor.

The MiniMed 780G with the Simplera Sync CGM and accompanying devices. [Image courtes…
Read more
  • 0

Insulet begins limited rollout of Omnipod 5 with Dexcom G7, grows sales by 38% in Q4

The Insulet Omnipod 5 [Photo courtesy of Insulet]Insulet (Nasdaq: PODD) + announced today that it began a limited market release of the Omnipod 5 with the Dexcom G7.

This marks the latest integration of Dexcom’s next-generation CGM into automated insulin delivery technology. Omnipod 5, Insulet’s newest patch pump offering, previously worked with the G6 in the U.S. It also recently integrated the system with Abbott’s FreeStyle Libre 2 Plus in Europe.

Insulet previously suggested that G7 integration would come early in 2024. In the company’s fourth-quarter earnings report — which included Street-beating results — the company confirmed the initial limited rollout began recently.

Shares of PODD fell nearly 7% at $183.50 apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — closed the day up 0.6%.…

Read more
  • 0

Insulet integrates Abbott FreeStyle Libre 2 Plus, Omnipod 5 in Europe

The Omnipod 5 with the Abbott FreeStyle Libre 2 Plus. [Image courtesy of Insulet]Insulet (Nasdaq: PODD) + announced today that it received CE mark approval for the integration of the Abbott (NYSE: ABT) + FreeStyle Libre 2 Plus with Omnipod 5.

European approval covers the compatibility of Abbott’s glucose sensor with the Insulet automated insulin delivery system for individuals aged two years and older with type 1 diabetes.

Currently, Omnipod 5 works with Dexcom CGM. Right now, it has compatibility with the previous-generation G6 as the companies work on integrating the G7. However, Insulet hinted at the future integration with Abbott’s popular FreeStyle Libre system midway through last year.

This also marks the second major insulin pump integration for Abbott in 2024. Last month, the company announced FreeStyle Libre 2 Plus compatibility with the Tandem Diabete…

Read more
  • 0

The top IVD and diabetes tech stories of 2023

The G7 CGM helps users manage their diabetes. [Image courtesy of Dexcom]Over the course of 2023, the medtech industry produced another impressive year of innovation, with news coming from a variety of spaces.

Chiefly among those were diabetes technologies and in vitro diagnostics (IVDs). We saw regulatory nods, product launches, funds raised and mergers fall apart.

Looking at those two spaces in particular, here are five diabetes and IVD stories that caught our attention in 2023:

5. Cytovale raises $84M Series C for sepsis diagnostic

In November, Cytovale announced that it raised $84 million in a Series C funding round to support its rapid sepsis diagnosis test. Cytovale earmarked funds to support the wider expansion of this testing technology.

The FDA cleared the IntelliSep test, which aids hospital emergency departments and health systems, in January. IntelliSep provides test results in under 10 minutes, offering actionable answers using standard b…

Read more
  • 0

Insulet enters into new credit agreement worth $487.5M in term loans

Insulet (Nasdaq: PODD) + announced that it entered into an amended credit agreement to replace existing term loans.

The automated insulin delivery technology developer entered into the agreement with Morgan Stanley Senior Funding. This agreement amended a credit agreement dated May 4, 2021. Pursuant to the agreement, the $487.5 million in term loans outstanding under the existing agreement was replaced with an equal amount of new term loans.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Insulet has new directors as former CEO is set to retire from board

Shacey Petrovic

Insulet (Nasdaq: PODD) + announced today that it named a duo of new board directors with high-profile figures set to retire.

Acton, Massachusetts-based Insulet appointed Flavia Pease and Timothy Stonesifer to its board. Former CEO Shacey Petrovic, along with Corinne Nevinny, intend to retire from the board in May.

Petrovic spent more than seven years as CEO at the automated insulin delivery technology developer. She stepped down from the corner office in May 2022 and remained on the board as Jim Hollingshead took over as CEO. Petrovic spent nearly six years on the board at Insulet, while Nevinny offered five years of service to the board.

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Insulet has a Class I recall for the Omnipod 5 Android App

Insulet’s Omnipod 5 with the Dexcom G6 CGM. [Image from Insulet]The FDA labeled a recall of the Insulet (NYSE: PODD) + Omnipod 5 App for Android smartphones as Class I, the most serious kind.

Insulet’s recall — a correction, not a product removal — affects software versions 1.1-1.2.3 for the Omnipod 5 automated insulin delivery system. It distributed the software between April 20, 2023, and Dec. 20, 2023. The company initiated the recall, which affects 28,919 devices in the U.S., on Nov. 7, 2023.

The Omnipod 5 App uses SmartAdjust technology to help adjust insulin delivery based on real-time and future blood sugar levels. Its SmartBolus Calculator computes recommended bolus doses, while the app considers user-inputted carbohydrates and other sensor data. The recalled app is an Android-based software provided on either a locked-down controller or downloaded on a smartphone. Its uses include activating/deactivat…

Read more
  • 0

The 10 biggest diabetes tech stories from 2023

Medtronic, EOFlow, Dexcom, Beta Bionics and Tandem Diabetes Care all contributed some of the biggest diabetes technology stories of 2023.

It was another banner year for diabetes technology, with regulatory approvals, product launches and M&A all playing their part.

Diabetes technology’s impressive 12 months marked a major trend across medtech as a whole, too.

In 2022, the diabetes space saw plenty of progress from some of its biggest names and this past year proved no different. Big hitters like Dexcom, Abbott, Medtronic, Insulet and more all contributed to some of the biggest stories in 2023. External factors — like popular GLP-1 drugs and big tech names looking to enter the space — also made the cut.

Here are 10 of the most intriguing diabetes technology stories from the past 12 months.

Medtronic was set to buy EOFlow — until it wasn’t

The medtech giant made a big splash in the insulin delivery space when it announced its plan to buy South K…

Read more
  • 0

Insulet applauds NICE guidance on hybrid closed loop insulin delivery

The Omnipod 5 hybrid closed-loop insulin delivery system worn on the back of an arm. [Image courtesy of Insulet]Insulet (Nasdaq: PODD) + supports new National Institute for Health and Care Excellence (NICE) guidance supporting automated insulin delivery for type 1 diabetes.

NICE published guidance recommending hybrid closed-loop systems for eligible people with type 1 diabetes in England and Wales.

Hybrid closed-loop systems, like the Insulet Omnipod 5, deliver insulin automatically based on calculations from glucose monitors. Medtronic, Tandem Diabetes Care and Beta Bionics also compete with Insulet in the automated insulin delivery space. Medtronic applauded automated insulin delivery recommendations from NICE last month.

NICE’s guidance, published this week, outlines that the systems require less input from the user, but manual insulin dosing is still needed sometimes, for example, around mealtimes. So, th…

Read more
  • 0

Report: There’s still ‘mutual interest’ with EOFlow, Medtronic despite deal falling through

Business Korea reports that EOFlow CEO Kim Jae-jin is leaving the door open with regard to the company’s collapsed deal with Medtronic (NYSE: MDT) + .

Medtronic announced this week that it terminated its $738 million agreement to acquire EOFlow, a maker of insulin patch pumps. The medtech giant cited “multiple breaches” of terms in the agreement as the reason behind the decision.

According to the Business Korea report, Jae-jin said the company itself terminated the acquisition contract with Medtronic.

He said both sides tried to find a mutual agreement over the past few weeks, citing “fundamental differences in perspective.” The CEO said Medtronic views ongoing legal disputes over IP with patch pump leader Insulet as “uncertain.”

Get the full story at our sister site, Drug Delivery Business News.

Read more
  • 0

Here’s what diabetes tech companies are doing on World Diabetes Day

Every November, the diabetes community comes together to recognize both National Diabetes Month in the U.S. and World Diabetes Day.

World Diabetes Day falls on today, Nov. 14, to mark the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles Herbert Best in 1922.

In an effort to drive awareness and understanding of the chronic condition, a number of medtech companies in the diabetes space undertake efforts each year to celebrate and draw attention to the day and month recognizing the community. We compiled lists in 2021 and 2022 to share some of the initiatives brought forward by these companies.

On World Diabetes Day in 2023, here is what medtech’s diabetes community is doing:


Abbott (NYSE:ABT) launched its new “Countdown at a Crossroads” initiative to mark National Diabetes Awareness Month.

The initiative features an animated installation promoting diabetes awareness at the Oculus Center…

Read more
  • 0

Insulet stock soars on Q3 results, Dexcom G7 integration planned for early 2024

Insulet (Nasdaq: PODD) + shares got a boost from third-quarter results that came in ahead of the consensus forecast.

Shares of PODD were up more than 16% at $162.94 near the end of trading today — a day after the company released results after market close. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — was up more than 2%.

Highlights for the quarter included FDA clearance for the Omnipod 5 app on Apple iOS and the limited launch of the Omnipod Go basal-only pump. Insulet also launched Omnipod 5 in Germany as it expects full European availability in 2024.

Perhaps the biggest news from Insulet’s third-quarter results was an update on a major integration development. The company said it’s on track to integrate Omnipod 5 with the Dexcom G7 by early 2024. Omnipod 5 already works with the Dexcom G6, while the company continues work on i…

Read more
  • 0